05/28/2026
The FDA has approved pivekimab sunirine-pvzy (DECNUPAZ, AbbVie) for adults with blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare and aggressive blood cancer with limited treatment options.
The approval was based on results from the CADENZA clinical trial, which showed complete remission or clinical complete remission in patients with both newly diagnosed and relapsed/refractory BPDCN.
This approval marks an important step forward in expanding treatment options for people living with rare blood cancers.
Read the full article here: https://healthtree.org/blastic-plasmacytoid-dendritic-cell-neoplasm/community/articles/05-27-2026-pivekimab-sunirine-pvzy-for-bpdcn?utm_source=&utm_medium=facebook&utm_campaign=socialmedia&utm_content=general